

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 June 2025 (05.06.2025)



(10) International Publication Number
WO 2025/114459 A1

(51) International Patent Classification:

C07D 513/14 (2006.01) A61P 35/00 (2006.01)
C07D 498/14 (2006.01) A61K 31/519 (2006.01)
C07D 471/14 (2006.01)

(21) International Application Number:

PCT/EP2024/083952

(22) International Filing Date:

28 November 2024 (28.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2318175.3 28 November 2023 (28.11.2023) GB
2318866.7 11 December 2023 (11.12.2023) GB
2407458.5 24 May 2024 (24.05.2024) GB

(71) Applicant: **GENOME THERAPEUTICS LTD** [GB/GB];
Regent House, 316 Beulah Hill, London SE19 3HF (GB).

(72) Inventors: **BALASUBRAMANIAN, Shankar**; c/o
Genome Therapeutics Ltd, Laboratory UB07, Yusuf
Hamied Department of Chemistry, University of Cam-
bridge, Lensfield Road Cambridge CB2 1EW (GB). **MEO,
Paul**; c/o Genome Therapeutics Ltd, Laboratory UB07,
Yusuf Hamied Department of Chemistry, University of
Cambridge, Lensfield Road Cambridge CB2 1EW (GB).

(74) Agent: **JOHNSON, Stephen**; 406 Cambridge Science
Park, Milton Road, Cambridge CB4 0WW (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,


TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: TETRACYCLIC COMPOUNDS FOR USE IN ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF CAN-
CER



(57) Abstract: The present invention provides compounds of Formula (I) and pharmaceuti-
cally acceptable salts and solvates thereof. The present invention also relates to antibody-drug con-
jugates (ADCs) comprising the compounds, to processes for the preparation of the compounds
and ADCs, as well as to ADCs and pharmaceutical compositions comprising them for use in the
treatment of cancer.

WO 2025/114459 A1